Horsetail

Two published case reports document virological breakthrough in HIV-positive patients on stable antiretroviral regimens (3TC/ZDV/EFV and FTC/TDF/EFV) after initiating Equisetum arvense supplementation. Proposed mechanisms include: CYP2B6/CYP3A4 induction by Equisetum flavonoids (increasing EFV metabolism), increased renal excretion of renally-cleared NRTIs (lamivudine, tenofovir, emtricitabine) through diuretic action, and possible absorption impairment.

Clinicians should advise HIV-positive patients on antiretroviral therapy to avoid Equisetum arvense until robust pharmacokinetic data are available. If virological breakthrough occurs in a patient using horsetail, discontinue the herb immediately and monitor viral load. This interaction is classified as high risk due to documented clinical consequences.

Equisetum arvense demonstrated diuretic activity comparable to hydrochlorothiazide 25 mg in a randomized double-blind clinical trial in healthy volunteers. Co-administration with pharmacological diuretics produces additive diuresis, potentially causing electrolyte disturbances—particularly hypokalemia, hyponatremia, and volume depletion—which are dangerous in elderly patients and those with cardiac disease.

Monitor electrolytes (potassium, sodium, magnesium) and volume status when horsetail is co-administered with pharmacological diuretics. This combination is particularly hazardous in patients also taking digoxin. Avoid concurrent use in the elderly or those with electrolyte disorders.

Equisetum arvense diuretic action causes urinary potassium loss leading to hypokalemia. Hypokalemia sensitizes the myocardium to digoxin toxicity by increasing binding of digoxin to Na/K-ATPase and reducing renal clearance. This electrolyte-mediated pharmacodynamic interaction can precipitate digoxin toxicity (arrhythmias, heart block, nausea, visual disturbances) at otherwise therapeutic digoxin plasma levels.

Avoid Equisetum arvense in patients on digoxin unless serum potassium and digoxin levels are closely monitored. Immediately evaluate any new symptoms in digoxin patients using horsetail. Signs of digoxin toxicity require urgent assessment and possible digoxin dose reduction.

Crude Equisetum arvense preparations contain thiaminase, an enzyme that destroys vitamin B1 (thiamine). Long-term use can cause thiamine deficiency by degrading both dietary and supplemental thiamine in the GI tract before absorption. Thiamine deficiency causes neurotoxicity including peripheral neuropathy and, in susceptible individuals, Wernicke-Korsakoff syndrome.

Use only standardized thiaminase-free horsetail preparations for any long-term use. Monitor thiamine status with extended supplementation. Avoid crude horsetail preparations in patients with thiamine deficiency risk factors (alcohol use disorder, malnutrition). Thiamine supplementation is ineffective if given concurrently with crude horsetail.

Equisetum arvense diuretic action increases urinary output and can alter sodium and lithium renal clearance. As lithium is predominantly excreted renally and its clearance parallels sodium handling, diuretic-induced sodium and volume depletion leads to compensatory renal lithium reabsorption, elevating serum lithium concentrations and increasing toxicity risk.

Monitor serum lithium levels carefully if horsetail is used by patients on lithium therapy. Warn patients about symptoms of lithium toxicity (tremor, polyuria, polydipsia, confusion, ataxia). Maintain adequate fluid and sodium intake to minimize volume depletion-related lithium elevation.

Corticosteroids promote urinary potassium wasting through mineralocorticoid receptor activation. Equisetum arvense diuretic activity causes additional urinary potassium excretion. Combined potassium-depleting effects can lead to severe hypokalemia with risk of muscle weakness, cardiac arrhythmias (particularly in patients also on digoxin), and impaired neuromuscular transmission.

Monitor serum potassium (K+) levels regularly when horsetail is co-administered with corticosteroids. Potassium supplementation may be necessary. Avoid prolonged concurrent use, particularly in patients with cardiac disease or on digoxin. Use the shortest effective course of horsetail.